Marker Therapeutics, Inc. announced its corporate and financial results for the full year ended December 31, 2024, reporting cash and cash equivalents of $19.2 million. The company projects its existing capital will fund operating expenses into the first quarter of 2026, with anticipated additional grant funding potentially extending this runway further.
Research and development expenses for fiscal year 2024 increased to $13.5 million from $10.4 million in 2023, reflecting ongoing clinical program advancements. General and administrative expenses decreased significantly to $4.2 million from $7.5 million in the prior year, demonstrating cost management efforts.
The net loss for the year was $10.7 million, compared to a net loss of $8.2 million in 2023. The company highlighted preliminary data from its Phase 1 APOLLO study, which showed a 78% objective response rate and a favorable safety profile in lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy.
Marker Therapeutics also secured over $13 million in non-dilutive funding from CPRIT and NIH SBIR programs to support its pancreatic and lymphoma clinical initiatives. Additionally, the United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee approved 'neldaleucel' as the nonproprietary name for MT-601.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.